Esophageal and Esophagogastric Junction Cancers, Version 1.2015

Jemal A, Bray F, Center MM. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.

JemalABrayFCenterMM. Global cancer statistics. CA Cancer J Clin2011;61:69–90. )| false
• Search Google Scholar
• Export Citation

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9–29.

SiegelRMaJZouZJemalA. Cancer statistics, 2014. CA Cancer J Clin2014;64:9–29. )| false
• Search Google Scholar
• Export Citation

Corley DA, Buffler PA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001;30:1415–1425.

CorleyDABufflerPA. Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol2001;30:1415–1425. )| false
• Search Google Scholar
• Export Citation

Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg 2003;76:S1367–1369.

PickensAOrringerMB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg2003;76:S1367–1369. )| false
• Search Google Scholar
• Export Citation

Siewert JR, Katja O. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2007;17:38–44.

SiewertJRKatjaO. Are squamous and adenocarcinomas of the esophagus the same disease?Semin Radiat Oncol2007;17:38–44. )| false
• Search Google Scholar
• Export Citation

Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white americans by sex, stage, and age. J Natl Cancer Inst 2008;100:1184–1187.

BrownLMDevesaSSChowWH. Incidence of adenocarcinoma of the esophagus among white americans by sex, stage, and age. J Natl Cancer Inst2008;100:1184–1187. )| false
• Search Google Scholar
• Export Citation

Siewert JR, Stein HJ, Feith M. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 2001;234:360–367.

SiewertJRSteinHJFeithM. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg2001;234:360–367. )| false
• Search Google Scholar
• Export Citation

Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual. 7th edition. New York, NY: Springer; 2010.

EdgeSBByrdDRComptonCC. AJCC Cancer Staging Manual.7th edition. New York, NY: Springer; 2010. )| false
• Search Google Scholar
• Export Citation

Rice TW, Rusch VW, Apperson-Hansen C. Worldwide esophageal cancer collaboration. Dis Esophagus 2009;22:1–8.

RiceTWRuschVWApperson-HansenC. Worldwide esophageal cancer collaboration. Dis Esophagus2009;22:1–8. )| false
• Search Google Scholar
• Export Citation

Kim TJ, Kim HY, Lee KW, Kim MS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics 2009;29:403–421.

KimTJKimHYLeeKWKimMS. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics2009;29:403–421. )| false
• Search Google Scholar
• Export Citation

Siewert JR. Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection. Dis Esophagus 1996;9:173–182.

SiewertJR. Carcinoma of the cardia: carcinoma of the gastroesophageal junction classification, pathology, and extent of resection. Dis Esophagus1996;9:173–182. )| false
• Search Google Scholar
• Export Citation

Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000;232:353–361.

SiewertJRFeithMWernerMSteinHJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg2000;232:353–361. )| false
• Search Google Scholar
• Export Citation

Hechtman JF, Polydorides AD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 2012;136:691–697.

HechtmanJFPolydoridesAD. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med2012;136:691–697. )| false
• Search Google Scholar
• Export Citation

Dreilich M, Wanders A, Brattstrom D. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus 2006;19:224–231.

DreilichMWandersABrattstromD. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus2006;19:224–231. )| false
• Search Google Scholar
• Export Citation

Reichelt U, Duesedau P, Tsourlakis MC. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120–129.

ReicheltUDuesedauPTsourlakisMC. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol2007;20:120–129. )| false
• Search Google Scholar
• Export Citation

Schoppmann SF, Jesch B, Friedrich J. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol 2010;34:1868–1873.

SchoppmannSFJeschBFriedrichJ. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol2010;34:1868–1873. )| false
• Search Google Scholar
• Export Citation

Moelans CB, van Diest PJ, Milne AN, Offerhaus GJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int 2011;2011:674182.

MoelansCBvan DiestPJMilneANOfferhausGJ. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int2011;2011:674182. )| false
• Search Google Scholar
• Export Citation

Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523–1529.

GravalosCJimenoA. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol2008;19:1523–1529. )| false
• Search Google Scholar
• Export Citation

Tanner M, Hollmen M, Junttila TT. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273–278.

TannerMHollmenMJunttilaTT. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol2005;16:273–278. )| false
• Search Google Scholar
• Export Citation

Bang Y, Chung H, Xu J. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 4556.

BangYChungHXuJ. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial [abstract]. J Clin Oncol2009;27(Suppl 15):Abstract 4556. )| false
• Search Google Scholar
• Export Citation

Hofmann M, Stoss O, Shi D. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797–805.

HofmannMStossOShiD. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology2008;52:797–805. )| false
• Search Google Scholar
• Export Citation

Ruschoff J, Dietel M, Baretton G. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299–307.

RuschoffJDietelMBarettonG. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch2010;457:299–307. )| false
• Search Google Scholar
• Export Citation

Bang YJ, Van Cutsem E, Feyereislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–697.

BangYJVan CutsemEFeyereislovaA. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet2010;376:687–697. )| false
• Search Google Scholar
• Export Citation

Barros-Silva JD, Leitao D, Afonso L. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009;100:487–493.

Barros-SilvaJDLeitaoDAfonsoL. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer2009;100:487–493. )| false
• Search Google Scholar
• Export Citation

van Hagen P, Hulshof MC, van Lanschot JJ. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–2084.

van HagenPHulshofMCvan LanschotJJ. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med2012;366:2074–2084. )| false
• Search Google Scholar
• Export Citation

Cunningham D, Allum WH, Stenning SP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.

CunninghamDAllumWHStenningSP. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med2006;355:11–20. )| false
• Search Google Scholar
• Export Citation

Steyerberg EW, Neville BA, Koppert LB. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006;24:4277–4284.

SteyerbergEWNevilleBAKoppertLB. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol2006;24:4277–4284. )| false
• Search Google Scholar
• Export Citation

Krasna MJ, Reed CE, Jaklitsch MT. Thoracoscopic staging of esophageal cancer: a prospective, multiinstitutional trial. Cancer and Leukemia Group B Thoracic Surgeons. Ann Thorac Surg 1995;60:1337–1340.

KrasnaMJReedCEJaklitschMT. Thoracoscopic staging of esophageal cancer: a prospective, multiinstitutional trial. Cancer and Leukemia Group B Thoracic Surgeons. Ann Thorac Surg1995;60:1337–1340. )| false
• Search Google Scholar
• Export Citation

Birkmeyer JD, Siewers AE, Finlayson EV. Hospital volume and surgical mortality in the United States. N Engl J Med 2002;346:1128–1137.

BirkmeyerJDSiewersAEFinlaysonEV. Hospital volume and surgical mortality in the United States. N Engl J Med2002;346:1128–1137. )| false
• Search Google Scholar
• Export Citation

Swisher SG, Wynn P, Putnam JB. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg 2002;123:175–183.

SwisherSGWynnPPutnamJB. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg2002;123:175–183. )| false
• Search Google Scholar
• Export Citation

Rusch VW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several? Semin Oncol 2004;31:444–449.

RuschVW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?Semin Oncol2004;31:444–449. )| false
• Search Google Scholar
• Export Citation

Siewert JR, Stein HJ, Feith M. Adenocarcinoma of the esophagogastric junction. Scand J Surg 2006;95:260–269.

SiewertJRSteinHJFeithM. Adenocarcinoma of the esophagogastric junction. Scand J Surg2006;95:260–269. )| false
• Search Google Scholar
• Export Citation

de Graaf GW, Ayantunde AA, Parsons SL. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol 2007;33:988–992.

de GraafGWAyantundeAAParsonsSL. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol2007;33:988–992. )| false
• Search Google Scholar
• Export Citation

Nath J, Moorthy K, Taniere P. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg 2008;95:721–726.

NathJMoorthyKTaniereP. Peritoneal lavage cytology in patients with oesophagogastric adenocarcinoma. Br J Surg2008;95:721–726. )| false
• Search Google Scholar
• Export Citation

Groth SS, Virnig BA, Whitson BA. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg 2010;139:612–620.

GrothSSVirnigBAWhitsonBA. Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the Surveillance Epidemiology and End Results database. J Thorac Cardiovasc Surg2010;139:612–620. )| false
• Search Google Scholar
• Export Citation

Peyre CG, Hagen JA, DeMeester SR. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008;248:979–985.

PeyreCGHagenJADeMeesterSR. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg2008;248:979–985. )| false
• Search Google Scholar
• Export Citation

Rizk NP, Ishwaran H, Rice TW. Optimum lymphadenectomy for esophageal cancer. Ann Surg 2010;251:46–50.

RizkNPIshwaranHRiceTW. Optimum lymphadenectomy for esophageal cancer. Ann Surg2010;251:46–50. )| false
• Search Google Scholar
• Export Citation

Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007;25:4110–4117.

KleinbergLForastiereAA. Chemoradiation in the management of esophageal cancer. J Clin Oncol2007;25:4110–4117. )| false
• Search Google Scholar
• Export Citation

Herskovic A, Martz K, al-Sarraf M. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593–1598.

HerskovicAMartzKal-SarrafM. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med1992;326:1593–1598. )| false
• Search Google Scholar
• Export Citation

Cooper JS, Guo MD, Herskovic A. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623–1627.

CooperJSGuoMDHerskovicA. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA1999;281:1623–1627. )| false
• Search Google Scholar
• Export Citation

Minsky BD, Pajak TF, Ginsberg RJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167–1174.

MinskyBDPajakTFGinsbergRJ. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol2002;20:1167–1174. )| false
• Search Google Scholar
• Export Citation

Li QQ, Liu MZ, Hu YH. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus 2010;23:253–259.

LiQQLiuMZHuYH. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus2010;23:253–259. )| false
• Search Google Scholar
• Export Citation

Ruppert BN, Watkins JM, Shirai K. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol 2010;33:346–352.

RuppertBNWatkinsJMShiraiK. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer. Am J Clin Oncol2010;33:346–352. )| false
• Search Google Scholar
• Export Citation

Meerten EV, van Rij C, Tesselaar ME. Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: a phase II study [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract e14508.

MeertenEVvan RijCTesselaarME. Definitive concurrent chemoradiation (CRT) with weekly paclitaxel and carboplatin for patients (pts) with irresectable esophageal cancer: a phase II study [abstract]. J Clin Oncol2010;28(Suppl 15):Abstract e14508. )| false
• Search Google Scholar
• Export Citation

Conroy T, Galais MP, Raoul JL. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305–314.

ConroyTGalaisMPRaoulJL. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol2014;15:305–314. )| false
• Search Google Scholar
• Export Citation

Iyer R, Wilkinson N, Demmy T, Javle M. Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol 2004;11:665–673.

IyerRWilkinsonNDemmyTJavleM. Controversies in the multimodality management of locally advanced esophageal cancer: evidence-based review of surgery alone and combined-modality therapy. Ann Surg Oncol2004;11:665–673. )| false
• Search Google Scholar
• Export Citation

Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538–543.

UrschelJDVasanH. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg2003;185:538–543. )| false
• Search Google Scholar
• Export Citation

Fiorica F, Di Bona D, Schepis F. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925–930.

FioricaFDi BonaDSchepisF. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut2004;53:925–930. )| false
• Search Google Scholar
• Export Citation

Sjoquist KM, Burmeister BH, Smithers BM. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011;12:681–692.

SjoquistKMBurmeisterBHSmithersBM. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol2011;12:681–692. )| false
• Search Google Scholar
• Export Citation

Swisher SG, Hofstetter W, Komaki R. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg 2010;90:892–898; discussion 898-899.

SwisherSGHofstetterWKomakiR. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg2010;90:892–898; discussion 898-899. )| false
• Search Google Scholar
• Export Citation

Cen P, Correa AM, Le JH. Adenocarcinoma of the lower esophagus with Barrett’s esophagus or without Barrett’s esophagus: differences in patients’ survival after preoperative chemoradiation. Dis Esophagus 2009;22:32–41.

CenPCorreaAMLeJH. Adenocarcinoma of the lower esophagus with Barrett’s esophagus or without Barrett’s esophagus: differences in patients’ survival after preoperative chemoradiation. Dis Esophagus2009;22:32–41. )| false
• Search Google Scholar
• Export Citation

Walsh TN, Noonan N, Hollywood D. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462–467.

WalshTNNoonanNHollywoodD. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med1996;335:462–467. )| false
• Search Google Scholar
• Export Citation

Bosset JF, Gignoux M, Triboulet JP. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161–167.

BossetJFGignouxMTribouletJP. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med1997;337:161–167. )| false
• Search Google Scholar
• Export Citation

Urba SG, Orringer MB, Turrisi A. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305–313.

UrbaSGOrringerMBTurrisiA. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol2001;19:305–313. )| false
• Search Google Scholar
• Export Citation

Bains MS, Stojadinovic A, Minsky B. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg 2002;124:270–277.

BainsMSStojadinovicAMinskyB. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg2002;124:270–277. )| false
• Search Google Scholar
• Export Citation

Kaklamanos IG, Walker GR, Ferry K. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol 2003;10:754–761.

KaklamanosIGWalkerGRFerryK. Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials. Ann Surg Oncol2003;10:754–761. )| false
• Search Google Scholar
• Export Citation

Burmeister BH, Smithers BM, Gebski V. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005;6:659–668.

BurmeisterBHSmithersBMGebskiV. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol2005;6:659–668. )| false
• Search Google Scholar
• Export Citation

Mariette C, Dahan L, Mornex F. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol 2014;32:2416–2422.

MarietteCDahanLMornexF. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol2014;32:2416–2422. )| false
• Search Google Scholar
• Export Citation

Oppedijk V, van der Gaast A, van Lanschot JJ. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol 2014;32:385–391.

OppedijkVvan der GaastAvan LanschotJJ. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol2014;32:385–391. )| false
• Search Google Scholar
• Export Citation

Tepper J, Krasna MJ, Niedzwiecki D. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086–1092.

TepperJKrasnaMJNiedzwieckiD. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol2008;26:1086–1092. )| false
• Search Google Scholar
• Export Citation

Burmeister BH, Thomas JM, Burmeister EA. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 2011;47:354–360.

BurmeisterBHThomasJMBurmeisterEA. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer2011;47:354–360. )| false
• Search Google Scholar
• Export Citation

Macdonald JS, Smalley SR, Benedetti J. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730.

MacdonaldJSSmalleySRBenedettiJ. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med2001;345:725–730. )| false
• Search Google Scholar
• Export Citation

Smalley SR, Benedetti JK, Haller DG. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327–2333.

SmalleySRBenedettiJKHallerDG. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol2012;30:2327–2333. )| false
• Search Google Scholar
• Export Citation

Bedard EL, Inculet RI, Malthaner RA. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer 2001;91:2423–2430.

BedardELInculetRIMalthanerRA. The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma. Cancer2001;91:2423–2430. )| false
• Search Google Scholar
• Export Citation

Rice TW, Adelstein DJ, Chidel MA. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg 2003;126:1590–1596.

RiceTWAdelsteinDJChidelMA. Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg2003;126:1590–1596. )| false
• Search Google Scholar
• Export Citation

Kofoed SC, Muhic A, Baeksgaard L. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg 2012;101:26–31.

KofoedSCMuhicABaeksgaardL. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction. Scand J Surg2012;101:26–31. )| false
• Search Google Scholar
• Export Citation

Adelstein DJ, Rice TW, Rybicki LA. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol 2009;4:1264–1269.

AdelsteinDJRiceTWRybickiLA. Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction. J Thorac Oncol2009;4:1264–1269. )| false
• Search Google Scholar
• Export Citation

Fuchs CS, Tepper JE, Niedzwiecki D. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101[abstract]. J Clin Oncol 2011;29(Suppl 15):Abstract 4003.

FuchsCSTepperJENiedzwieckiD. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101[abstract]. J Clin Oncol2011;29(Suppl 15):Abstract 4003. )| false
• Search Google Scholar
• Export Citation

Kelsen DP, Ginsberg R, Pajak TF. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979–1984.

KelsenDPGinsbergRPajakTF. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med1998;339:1979–1984. )| false
• Search Google Scholar
• Export Citation

Kelsen DP, Winter KA, Gunderson LL. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007;25:3719–3725.

KelsenDPWinterKAGundersonLL. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol2007;25:3719–3725. )| false
• Search Google Scholar
• Export Citation

Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727–1733.

Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet2002;359:1727–1733. )| false
• Search Google Scholar
• Export Citation

Allum WH, Stenning SP, Bancewicz J. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009;27:5062–5067.

AllumWHStenningSPBancewiczJ. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol2009;27:5062–5067. )| false
• Search Google Scholar
• Export Citation

Boonstra JJ, Kok TC, Wijnhoven BP. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer 2011;11:181.

BoonstraJJKokTCWijnhovenBP. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer2011;11:181. )| false
• Search Google Scholar
• Export Citation

Thirion PG, Michiels S, Le Maitre A. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma [abstract]. J Clin Oncol 2007;25(Suppl 18):Abstract 4512.

ThirionPGMichielsSLe MaitreA. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma [abstract]. J Clin Oncol2007;25(Suppl 18):Abstract 4512. )| false
• Search Google Scholar
• Export Citation

Ychou M, Boige V, Pignon JP. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715–1721.

YchouMBoigeVPignonJP. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol2011;29:1715–1721. )| false
• Search Google Scholar
• Export Citation

Leichman L, Berry BT. Experience with cisplatin in treatment regimens for esophageal cancer. Semin Oncol 1991;18:64–72.

LeichmanLBerryBT. Experience with cisplatin in treatment regimens for esophageal cancer. Semin Oncol1991;18:64–72. )| false
• Search Google Scholar
• Export Citation

Muhr-Wilkenshoff F, Hinkelbein W, Ohnesorge I. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis 2003;18:330–334.

Muhr-WilkenshoffFHinkelbeinWOhnesorgeI. A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis2003;18:330–334. )| false
• Search Google Scholar
• Export Citation

Enzinger PC, Kulke MH, Clark JW. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005;50:2218–2223.

EnzingerPCKulkeMHClarkJW. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci2005;50:2218–2223. )| false
• Search Google Scholar
• Export Citation

Burkart C, Bokemeyer C, Klump B. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res 2007;27:2845–2848.

BurkartCBokemeyerCKlumpB. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res2007;27:2845–2848. )| false
• Search Google Scholar
• Export Citation

Muro K, Hamaguchi T, Ohtsu A. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15:955–959.

MuroKHamaguchiTOhtsuA. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol2004;15:955–959. )| false
• Search Google Scholar
• Export Citation

Albertsson M, Johansson B, Friesland S. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol 2007;24:407–412.

AlbertssonMJohanssonBFrieslandS. Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer. Med Oncol2007;24:407–412. )| false
• Search Google Scholar
• Export Citation

Ajani JA, Ilson DH, Daugherty K. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994;86:1086–1091.

AjaniJAIlsonDHDaughertyK. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst1994;86:1086–1091. )| false
• Search Google Scholar
• Export Citation

Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007;18:898–902.

IlsonDHWadleighRGLeichmanLPKelsenDP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol2007;18:898–902. )| false
• Search Google Scholar
• Export Citation

Harstrick A, Bokemeyer C, Preusser P. Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol 1992;29:321–322.

HarstrickABokemeyerCPreusserP. Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. Cancer Chemother Pharmacol1992;29:321–322. )| false
• Search Google Scholar
• Export Citation

Ilson DH, Ajani J, Bhalla K. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998;16:1826–1834.

IlsonDHAjaniJBhallaK. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol1998;16:1826–1834. )| false
• Search Google Scholar
• Export Citation

Petrasch S, Welt A, Reinacher A. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998;78:511–514.

PetraschSWeltAReinacherA. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer1998;78:511–514. )| false
• Search Google Scholar
• Export Citation

Ilson DH, Forastiere A, Arquette M. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000;6:316–323.

IlsonDHForastiereAArquetteM. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J2000;6:316–323. )| false
• Search Google Scholar
• Export Citation

Ajani JA, Fodor MB, Tjulandin SA. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005;23:5660–5667.

AjaniJAFodorMBTjulandinSA. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol2005;23:5660–5667. )| false
• Search Google Scholar
• Export Citation

Van Cutsem E, Moiseyenko VM, Tjulandin S. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991–4997.

Van CutsemEMoiseyenkoVMTjulandinS. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol2006;24:4991–4997. )| false
• Search Google Scholar
• Export Citation

Kim JY, Do YR, Park KU. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol 2010;66:31–36.

KimJYDoYRParkKU. A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer. Cancer Chemother Pharmacol2010;66:31–36. )| false
• Search Google Scholar
• Export Citation

Al-Batran SE, Hartmann JT, Hofheinz R. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008;19:1882–1887.

Al-BatranSEHartmannJTHofheinzR. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol2008;19:1882–1887. )| false
• Search Google Scholar
• Export Citation

Shankaran V, Mulcahy MF, Hochster HS. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: preliminary results of a phase II study [abstract]. Presented at 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 47.

ShankaranVMulcahyMFHochsterHS. Docetaxel, oxaliplatin, and 5-fluorouracil for the treatment of metastatic or unresectable gastric or gastroesophageal junction (GEJ) adenocarcinomas: preliminary results of a phase II study [abstract]. Presented at 2009 ASCO Gastrointestinal Cancers Symposium; January 15–17, 2009; San Francisco, California. Abstract 47. )| false
• Search Google Scholar
• Export Citation

Overman MJ, Kazmi SM, Jhamb J. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 2010;116:1446–1453.

OvermanMJKazmiSMJhambJ. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer2010;116:1446–1453. )| false
• Search Google Scholar
• Export Citation

Tebbutt NC, Cummins MM, Sourjina T. Randomised, noncomparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 2010;102:475–481.

TebbuttNCCumminsMMSourjinaT. Randomised, noncomparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer2010;102:475–481. )| false
• Search Google Scholar
• Export Citation

Stein A, Arnold D, Thuss-Patience PC. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastroesophageal cancer: results of a multicenter phase I/II study. Acta Oncol 2014;53:392–398.

SteinAArnoldDThuss-PatiencePC. Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastroesophageal cancer: results of a multicenter phase I/II study. Acta Oncol2014;53:392–398. )| false
• Search Google Scholar
• Export Citation

Cunningham D, Starling N, Rao S. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46.

CunninghamDStarlingNRaoS. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med2008;358:36–46. )| false
• Search Google Scholar
• Export Citation

Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004;18:22–25.

IlsonDH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park)2004;18:22–25. )| false
• Search Google Scholar
• Export Citation

Dank M, Zaluski J, Barone C. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008;19:1450–1457.

DankMZaluskiJBaroneC. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2008;19:1450–1457. )| false
• Search Google Scholar
• Export Citation

Wolff K, Wein A, Reulbach U. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs 2009;20:165–173.

WolffKWeinAReulbachU. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial. Anticancer Drugs2009;20:165–173. )| false
• Search Google Scholar
• Export Citation

Burtness B, Gibson M, Egleston B. Phase II trial of docetaxelirinotecan combination in advanced esophageal cancer. Ann Oncol 2009;20:1242–1248.

BurtnessBGibsonMEglestonB. Phase II trial of docetaxelirinotecan combination in advanced esophageal cancer. Ann Oncol2009;20:1242–1248. )| false
• Search Google Scholar
• Export Citation

Lustberg MB, Bekaii-Saab T, Young D. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol 2010;5:713–718.

LustbergMBBekaii-SaabTYoungD. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. J Thorac Oncol2010;5:713–718. )| false
• Search Google Scholar
• Export Citation

Moehler M, Kanzler S, Geissler M. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2010;21:71–77.

MoehlerMKanzlerSGeisslerM. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol2010;21:71–77. )| false
• Search Google Scholar
• Export Citation

Guimbaud R, Louvet C, Ries P. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol 2014;32:3520–3526.

GuimbaudRLouvetCRiesP. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French Intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. J Clin Oncol2014;32:3520–3526. )| false
• Search Google Scholar
• Export Citation

Assersohn L, Brown G, Cunningham D. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004;15:64–69.

AssersohnLBrownGCunninghamD. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol2004;15:64–69. )| false
• Search Google Scholar
• Export Citation

Leary A, Assersohn L, Cunningham D. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol 2009;64:455–462.

LearyAAssersohnLCunninghamD. A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy. Cancer Chemother Pharmacol2009;64:455–462. )| false
• Search Google Scholar
• Export Citation

Mauer AM, Kraut EH, Krauss SA. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol 2005;16:1320–1325.

MauerAMKrautEHKraussSA. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol2005;16:1320–1325. )| false
• Search Google Scholar
• Export Citation

Al-Batran SE, Hartmann JT, Probst S. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435–1442.

Al-BatranSEHartmannJTProbstS. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol2008;26:1435–1442. )| false
• Search Google Scholar
• Export Citation

El-Rayes BF, Shields A, Zalupski M. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol 2004;15:960–965.

El-RayesBFShieldsAZalupskiM. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol2004;15:960–965. )| false
• Search Google Scholar
• Export Citation

Ross P, Nicolson M, Cunningham D. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996–2004.

RossPNicolsonMCunninghamD. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol2002;20:1996–2004. )| false
• Search Google Scholar
• Export Citation

Urba SG, Chansky K, VanVeldhuizen PJ. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group study. Invest New Drugs 2004;22:91–97.

UrbaSGChanskyKVanVeldhuizenPJ. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group study. Invest New Drugs2004;22:91–97. )| false
• Search Google Scholar
• Export Citation

Millar J, Scullin P, Morrison A. Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer. Br J Cancer 2005;93:1112–1116.